Erufosine suppresses breast cancer in vitro and in vivo for its activity on PI3K, c-Raf and Akt proteins

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 11, 2012, Pages 1909-1917

  Dineva, Ilina K ^a,b   Zaharieva, Maya M ^a   Konstantinov, Spiro M ^b   Eibl, Hansjörg ^c   Berger, Martin R ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

Akt; Breast carcinoma; Erufosine; PI3K; Raf; Ras

Indexed keywords

ANTINEOPLASTIC AGENT; ERUFOSINE; ESTROGEN RECEPTOR; METHYLNITROSOUREA; MITOGEN ACTIVATED PROTEIN KINASE; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TUMOR REGRESSION; WEIGHT REDUCTION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOBLOTTING; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELLS; METHYLNITROSOUREA; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR STRUCTURE; ORGANOPHOSPHATES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RAF; QUATERNARY AMMONIUM COMPOUNDS; RAS PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TUMOR BURDEN; WEIGHT LOSS;

EID: 84870426243     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1271-6     Document Type: Article

References (45)

1. Bagley RG, Kurtzberg L, Rouleau C, Yao M, Teicher BA (2011) Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells. Cancer Chemother Pharmacol 68(6): 1537-1546. doi:10.1007/s00280- 011-1658-0
2. Basu A (2008) Molecular targets of breast cancer: AKTing in concert. Breast Cancer (Auckl) 2: 11-16
3. Bauerle T, Peterschmitt J, Hilbig H, Kiessling F, Armbruster FP, Berger MR (2006) Treatment of bone metastasis induced by MDA-MB-231 breast cancer cells with an antibody against bone sialoprotein. Int J Oncol 28(3): 573-583
4. Bendell JC, Nemunaitis J, Vukelja SJ, Hagenstad C, Campos LT, Hermann RC, Sportelli P, Gardner L, Richards DA (2011) Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol 29(33): 4394-4400. doi:10.1200/JCO.2011.36.1980
5. Berger M, Habs M, Schmahl D (1983) Noncarcinogenic chemotherapy with a combination of vincristine, methotrexate and 5-fluorouracil (VMF) in rats. Int J Cancer 32(2): 231-236 (Pubitemid 13038951)
6. Berger MR, Muschiol C, Schmahl D, Eibl HJ (1987) New cytostatics with experimentally different toxic profiles. Cancer Treat Rev 14(3-4): 307-317 (Pubitemid 18065032)
7. Berger MR, Yanapirut P, Reinhardt M, Klenner T, Scherf HR, Schmeiser HH, Eibl H (1992) Antitumor activity of alkylphosph-ocholines and analogues in methylnitrosourea-induced rat mammary carcinomas. Prog Exp Tumor Res 34: 98-115
8. Berger MR, Betsch B, Gebelein M, Amtmann E, Heyl P, Scherf HR (1993) Hexadecylphosphocholine differs from conventional cytostatic agents. J Cancer Res Clin Oncol 119(9): 541-548 (Pubitemid 23180045)
9. Berger MR, Sobottka S, Konstantinov SM, Eibl H (1998) Erucylphosphocholine is the prototype of i.v. injectable alkylphosphocholines. Drugs Today 34: 73-81 (Pubitemid 29046798)
10. Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49(17): 4682-4689 (Pubitemid 19213607)
11. Calabretta B, Perrotti D (2004) The biology of CML blast crisis. Blood 103(11): 4010-4022. doi:10.1182/blood-2003-12-4111 (Pubitemid 38685338)
12. Eibl H, Engel J (1992) Synthesis of hexadecylphosphocholine (miltefosine). Prog Exp Tumor Res 34: 1-5
13. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8): 550-562. doi:10.1038/nrc2664
14. Ergezinger K, Vehmeyer K, Unger C (1999) Stimulation of human hematopoietic progenitor cells by the alkylphosphocholines hexadecylphosphocholine and hexadecyl-N, N, N-trimethyl-hexa-nolamine. Anticancer Res 19 (4B): 3213-3219 (Pubitemid 30042612)
15. Geilen CC, Haase R, Buchner K, Wieder T, Hucho F, Reutter W (1991) The phospholipid analogue, hexadecylphosphocholine, inhibits protein kinase C in vitro and antagonises phorbol ester-stimulated cell proliferation. Eur J Cancer 27(12): 1650-1653
16. Georgieva MC, Konstantinov SM, Topashka-Ancheva M, Berger MR (2002) Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells. Cancer Lett 182(2): 163-174 (Pubitemid 34621180)
17. Grant S (2008) Cotargeting survival signaling pathways in cancer. J Clin Invest 118(9): 3003-3006. doi:10.1172/JCI36898
18. Hilgard P, Stekar J, Voegeli R, Harleman JH (1992) Experimental therapeutic studies with miltefosine in rats and mice. Prog Exp Tumor Res 34: 116-130
19. Hilgard P, Klenner T, Stekar J, Unger C (1993) Alkylphosphocho-lines: a new class of membrane-active anticancer agents. Cancer Chemother Pharmacol 32(2): 90-95 (Pubitemid 23131925)
20. Hilgard P, Pohl J, Engel J (1997) The development of alkylphosph- ocholines as signal transduction inhibitors: experimental and clinical challenges. J Cancer Res Clin Oncol 123(5): 286-287 (Pubitemid 27230905)
21. Jendrossek V, Hammersen K, Erdlenbruch B, Kugler W, Krugener R, Eibl H, Lakomek M (2002) Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro. Cancer Chemother Pharmacol 50(1): 71-79. doi:10.1007/s00280-002-0440-8 (Pubitemid 34743999)
22. Kapoor V, Zaharieva MM, Das SN, Berger MR (2012) Erufosine simultaneously induces apoptosis and autophagy by modulating the Akt-mTOR signaling pathwayinoral squamous cell carcinoma. Cancer Lett 319(1): 39-48. doi:10.1016/j.canlet.2011.12.032
23. Konigs SK, Pallasch CP, Lindner LH, Schwamb J, Schulz A, Brinker R, Claasen J, Veldurthy A, Eibl H, Hallek M, Wendtner CM (2010) Erufosine, a novel alkylphosphocholine, induces apoptosis in CLL through a caspase-dependent pathway. Leuk Res 34(8): 1064-1069. doi:10.1016/j.leukres.2009.12.003
24. Konstantinov SM, Berger MR (1999) Human urinary bladder carcinoma cell lines respond to treatment with alkylphosphoch-olines. Cancer Lett 144(2): 153-160 (Pubitemid 29457657)
25. Konstantinov SM, Kaminsky R, Brun R, Berger MR, Zillmann U (1997) Efficacy of anticancer alkylphosphocholines in Trypan-osoma brucei subspecies. Acta Trop 64(3-4): 145-154 (Pubitemid 27191478)
26. Konstantinov SM, Eibl H, Berger MR (1998a) Alkylphosphocholines induce apoptosis in HL-60 and U-937 leukemic cells. Cancer Chemother Pharmacol 41(3): 210-216 (Pubitemid 28094044)
27. Konstantinov SM, Topashka-Ancheva M, Benner A, Berger MR (1998b) Alkylphosphocholines: effects on human leukemic cell lines and normal bone marrow cells. Int J Cancer 77(5): 778-786 (Pubitemid 28341397)
28. Konstantinov SM, Eibl H, Berger MR (1999) BCR-ABL influences the antileukaemic efficacy of alkylphosphocholines. Br J Haematol 107(2): 365-380
29. Kotting J, Berger MR, Unger C, Eibl H (1992) Alkylphosphocholines: influence of structural variation on biodistribution at antineop-lastically active concentrations. Cancer Chemother Pharmacol 30(2): 105-112
30. Koziol JA, Maxwell DA, Fukushima M, Colmerauer ME, Pilch YH (1981) A distribution-free test for tumor-growth curve analyses with application to an animal tumor immunotherapy experiment. Biometrics 37(2): 383-390
31. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773(8): 1263-1284. doi:10.1016/j.bbamcr.2006.10.001 (Pubitemid 47125967)
32. Mendelsohn J (2008) The molecular basis of cancer. Saunders Elsevier, Philadelphia
33. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1-2): 55-63 (Pubitemid 14203433)
34. Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M, Martin T, Schlossman R, Ghobrial IM, Munshi N, Laubach J, Allerton J, Hideshima T, Colson K, Poradosu E, Gardner L, Sportelli P, Anderson KC (2011) Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol 29(32): 4243-4249. doi:10.1200/JCO.2010.33.9788
35. Richardson PG, Eng C, Kolesar J, Hideshima T, Anderson KC (2012) Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacoki-netics, and clinical activity. Expert Opin Drug Metab Toxicol 8(5): 623-633. doi:10.1517/17425255.2012.681376
36. Rudner J, Ruiner CE, Handrick R, Eibl HJ, Belka C, Jendrossek V (2010) The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat Oncol 5:108. doi:10.1186/1748-717X-5-108
37. Sobottka SB, Berger MR (1992) Assessment of antineoplastic agents by MTT assay: partial underestimation of antiproliferative properties. Cancer Chemother Pharmacol 30(5): 385-393
38. Sobottka SB, Berger MR, Eibl H (1993) Structure-activity relationships of four anti-cancer alkylphosphocholine derivatives in vitro and in vivo. Int J Cancer 53(3): 418-425 (Pubitemid 23047889)
39. Toker A, Yoeli-Lerner M (2006) Akt signaling and cancer: surviving but not moving on. Cancer Res 66(8): 3963-3966. doi:10.1158/0008-5472.CAN-06-0743
40. Wickenden JA, Watson CJ (2010) Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: a play in 3 Akts. Breast Cancer Res 12(2):202. doi:10.1186/bcr2558
41. Wu R, Hu TC, Rehemtulla A, Fearon ER, Cho KR (2011) Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res 17(23): 7359-7372. doi:10.1158/1078-0432.CCR-11- 1388
42. Yosifov DY, Dineva IK, Zaharieva MM, Konstantinov SM, Berger MR (2007) The expression level of the tumor suppressor retinoblastoma protein (Rb) influences the antileukemic efficacy of erucylphospho-N, N, N- trimethylpropylammonium (ErPC3). Cancer Biol Ther 6(6): 930-935 (Pubitemid 351574984)
43. Yosifov DY, Konstantinov SM, Berger MR (2009) Erucylphospho-N, N, N-trimethylpropylammonium shows substantial cytotoxicity in multiple myeloma cells. Ann N Y Acad Sci 1171: 350-358. doi:10.1111/j.1749-6632.2009.04694.x
44. Yosifov DY, Todorov PT, Zaharieva MM, Georgiev KD, Pilicheva BA, Konstantinov SM, Berger MR (2011) Erucylphospho-N, N, N-trimethylpropylammonium (erufosine) is a potential antimye-loma drug devoid of myelotoxicity. Cancer Chemother Pharmacol 67(1): 13-25. doi:10.1007/s00280-010-1273-5
45. Zaharieva MM, Konstantinov SM, Pilicheva B, Karaivanova M, Berger MR (2007) Erufosine: a membrane targeting antineoplastic agent with signal transduction modulating effects. Ann N Y Acad Sci 1095: 182-192. doi:10.1196/annals.1397.022 (Pubitemid 47092450)